Serum interleukin-2, interleukin-6, tumour necrosis factor-alpha and nitric oxide levels in patients with Behçet's disease

Annals of the Academy of Medicine Singapore

Volumn 33, Issue 5, 2004, Pages 596-599

  Akdeniz, Necmettin ^a   Esrefoglu, M ^b   Keles M S ^c   Karakuzu, A ^c   Atasoy, M ^c  

^a YUZUNCU YIL UNIVERSITY   (Turkey)

^b INONU UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^c ATATURK UNIVERSITY   (Turkey)

Author keywords

Cytokine; Skin disease; Vasculitis

Indexed keywords

CYTOKINE; INTERLEUKIN 2; NITRIC OXIDE; REACTIVE NITROGEN SPECIES; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; BEHCET DISEASE; BLOOD LEVEL; CLINICAL ARTICLE; COLORIMETRY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MALE; PATHOGENESIS;

EID: 10344258543     PISSN: 03044602     EISSN: 29724066     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Behçet H. Über rezidivierende, aphtöse, durch ein Virus verursachte Geschwüre am Mund, am Auge und an den Genitalien. Dermatologische Wochenschrift, Hamburg 1937;105:1152-63.
2. Jorizzo JL. Behçet's disease. In: Freedberg IM, Eisen AZ, Wolf K, Austen KF, Goldsmith LA, Katz SI, editors. Fitzpatrick's Dermatology in General Medicine. 5th ed. New York: McGraw-Hill, 1999:2161-5.
3. Jorizzo JL, Hudson RD, Schmalstieg FC, Daniels JC, Apisarnthanarax P, Henry JC, et al. Behçet's syndrome: immune regulation, circulating immune complexes, neutrophil migration, and colchicine therapy. J Am Acad Dermatol 1984;10:205-14.
4. Evereklioglu C, Er H, Turkoz Y, Cekmen M. Serum levels of TNF-alpha, sIL-2R, IL-6, and IL-8 are increased and associated with elevated lipid peroxidation in patients with Behcet's disease. Mediators Inflamm 2002;11:87-93.
5. Sahin S, Akoglu T, Direskeneli H, Sen LS, Lawrence R. Neutrophil adhesion to endothelial cells and factors affecting adhesion in patients with Behçet's disease. Ann Rheum Dis 1996;55:128-33.
6. Basoglu M, Kiziltunç A, Akçay F, Keles S, Gündogdu C, Ören D. Tumor necrosis factor-α and interleukin-6 in peritoneal adhesion formation. Turk J Med Sci 1998;28:253-8.
7. Sayinalp N, Özcebe OI, Özdemir O, Haznedaroglu IC, Dündar S, Kirazli S. Cytokines in Behçet's disease. J Rheumatol 1996;23:321-2.
8. Lin H, Wei RQ, Boiling SF. Tumor necrosis factor-α and interferon-γ modulation of nitric oxide and allograft survival. J Surg Res 1995;59: 103-10.
9. Kozawa O, Tokuda H, Kaida T, Matsuno H, Uematsu T. Thrombin regulates interleukin-6 synthesis through phosphatidylcholine hydrolysis by phospholipase D in osteoblasts. Arch Biochem Biophys 1997;345: 10-5.
10. Sugi N, Nakazawa M, Nakamura S, Minami M, Ohno S. Analysis of the profile of CD4+ cells in Behçet's disease (Japanase). Nippon Ganka Gakkai Zasshi 1997;101:335-40.
11. Kallen KJ. The role of transsignalling via the agonistic soluble IL-6 receptor in human diseases. Biochem Biophys Acta 2002;1592:323-43.
12. Heinrich PC, Castell JV, Andus T. Interleukin-6 and the acute phase response. Biochem J 1990;265:621-36.
13. Hirano T. Interleukin-6 and its relation to inflammation and disease. Clin Immunol Immunopathol 1992;62:60-5.
14. Bruch-Gerharz D, Ruzicka T, Kolb-Bachofen V. Nitric oxide and its implications in skin homeostasis and disease: a review. Arch Dermatol Res 1998;290:643-51.
15. Moshage H. Moshage H. Nitric oxide determinations: much ado about NO.-thing? Clin Chem 1997;43:553-6.
16. Jackson M, Frame F, Weller R, McKenzie RC. Expression of nitric oxide synthase III (eNOS) mRNA by human skin cells: melanocytes but not keratinocytes express eNOS mRNA. Arch Dermatol Res 1998;290: 350-2.
17. Wang R, Ghahary A, Shen YJ, Scott PG, Tredget EE. Human dermal fibroblasts produce nitric oxide and express both constitutive and inducible nitric oxide synthase isoforms. J Invest Dermatol 1996;106: 419-27.
18. Baudouin JE, Tachon P. Constitutive nitric oxide synthase is present in normal human keratinocytes. J Invest Dermatol 1996;106: 428-31.
19. Kroncke KD, Fehsel K, Kolb-Bachofen V. Inducible nitric oxide synthase in human diseases. Clin Exp Immunol 1998;113:147-56.
20. Schmilz-Huebner U, Knop J. Evidence for an endothelial cell dysfunction in association with Behcet's disease. Thromb Res 1984;34:277-85.
21. Behrendt D, Ganz P. Endothelial function. From vascular biology to clinical applications. Am J Cardiol 2002;90:40-8.
22. Wagner L, Hoey JG, Erdely A, Boegehold MA, Baylis C. The nitric oxide pathway is amplified in venular vs arteriolar cultured rat mesenteric endothelial cells. Microvasc Res 2001;62:401-9.
23. International Study Group for Behçet's Disease. Criteria for diagnosis of Behçet's disease. Lancet 1990;335:1078-80.
24. Akyol Ö, Herken H, Uz E, Fadillioglu, Ünal S, Sögüt S, et al. The indices of endogenous oxidative and antioxidative processes in plasma from schizophrenic patients. The possible role of oxidant/antioxidant imbalance. Prog Neuropsychopharmacol Biol Psychiatry 2002;26:995-1005.
25. Alpsoy E, Çayirli C, Er H, Yilmaz E. The levels of plasma interleukin-2 and soluble interleukin-2R in Behçet's disease: a marker of disease activity. J Dermatol 1998;25:513-6.
26. Turan B, Gallati H, Erdi H, Gürler A, Michel BA, Villiger PM. Systemic levels of the T cell regulatory cytokines IL-10 and IL-12 in Behçet's disease: soluble TNFR-75 as a biological marker of disease activity. J Rheumatol 1997;24:128-32.
27. Raziuddin S, al-Dalaan A, Bahabri S, Siraj AK, al-Sedairy S. Divergent cytokine production profile in Behçet's disease. Altered Th1/Th2 cell cytokine pattern. J Rheumatol 1998;25:329-33.
28. Evans CA, Jellis J, Hughes SP, Remick DG, Friedland JS. Tumour necrosis factor-alpha, interleukin-6, and interleukin-8 secretion and the acutephase response in patients with bacterial and tuberculous osteomyelitis. J Infect Dis 1998;177:1582-7.
29. al-Dalaan A, al-Sedairy S, al-Balaa S, al-Janadi M, Elramahi K, Bahabri S, et al. Enhanced interleukin-8 secretion in circulation of patients with Behçet's disease. J Rheumatol 1995;22:904-7.
30. Alien JB, Keng T, Privalle C. Nitric oxide and peroxynitrite production in ocular inflammation. Environ Health Perspect 1998;106:1145-9.
31. Wanchu A, Khullar M, Deodhar SD, Bambery P, Sud A. Nitric oxide synthesis is increased in patients with systemic lupus erythematosus. Rheumatol Int 1998;18:41-3.
32. Brundin L, Svenungsson E, Morcos E, Andersson M, Olsson T, Lundberg I, et al. Central nervous system nitric oxide formation in cerebral systemic lupus erythematosus. Ann Neurol 1998;44:704-6.
33. Pham TN, Rahman P, Tobin YM, Khraishi MM, Hamilton SF, Alderdice C, et al. Elevated serum nitric oxide levels in patients with inflammatory arthritis associated with co-expression of inducible nitric oxide synthase and protein kinase C-eta in peripheral blood monocyte-derived macrophages. J Rheumatol 2003;30:2529-34.
34. Senturk MU, Senturk UK, Basak PY, Kuru O, Yesilkaya A. Serum and skin nitrite levels in patients with Behçet's disease. J Eur Acad Dermatol Venereol 2003;17:614-5.
35. Sancak B, Onder M, Oztas MO, Bukan N, Gurer MA. Nitric oxide levels in Behcet's disease. J Eur Acad Dermatol Venereol 2003;17:7-9.
36. Orem A, Vanizor B, Cimsit G, Kiran E, Deger O, Malkoc M. Decreased nitric oxide production in patients with Behcet's disease. Dermatology 1999;198:33-6.